3720-03-4

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Imidazolidinedione, 5,5-dimethyl-1-(phenylmethyl)is used as an anticonvulsant for the treatment and prevention of seizures. It helps stabilize the electrical activity in the brain, preventing the excessive firing of neurons that can lead to seizures.
2,4-Imidazolidinedione, 5,5-dimethyl-1-(phenylmethyl)is also used as an antiarrhythmic medication for the treatment of certain types of abnormal heart rhythms, contributing to the regulation of heart rhythm and preventing complications associated with arrhythmias.
Common side effects of phenytoin include dizziness, nausea, and drowsiness, and it can interact with a wide range of other medications, making it essential to consider potential drug interactions when prescribing and administering this medication.

Upstream product

• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 1413431-92-1 (3-benzyl-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)methyl pivalate 

Downstream Products

• 1413431-95-4 2-(3-benzyl-4,4-dimethyl-2-oxo-5-thioxoimidazolidin-1-yl)propionic acid ethyl ester 
• 1413431-98-7 7-benzyl-4,8,8-trimethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione 
• 1413432-00-4 7-benzyl-2,4,8,8-tetramethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione 
• 1413432-02-6 7-benzyl-4,8,8-trimethyl-2-(prop-2-ynyl)-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione 

Relevant academic research and scientific papers

Regioselective synthesis of 7,8-dihydroimidazo [5,1-c][1,2,4]triazine-3, 6(2H,4H)-dione derivatives: A new drug-like heterocyclic scaffold

Dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione derivatives were prepared by successive N3- and N1-alkylation of hydantoins, followed by regioselective thionation and subsequent cyclization under mild conditions. In a final alkylation step a further substituent may be introduced. The synthetic strategy allows broad structural variation of this new drug-like heterobicyclic scaffold. In addition to extensive NMR and MS analyses, the structure of one derivative was confirmed by X-ray crystallography.

N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES

Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Reverse hydroxamate inhibitors of matrix metalloproteinases

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Ring-Transformation of Imidazolidine-2,4-diones ( = Hydantoins ) to 4H-Imidazoles in the Reaction with 3-(Dimethylamino)-2,2-dimethyl-2H-azirines

At ca. 70 deg C, 3-(dimethylamino)-2,2-dimethyl-2H-azirine (1) and 5,5-disubstituted hydantoins 4 in MeCN or i-PrOH give 2-(1-aminoalkyl)-5-(dimethylamino)-4,4-dimethyl-4H-imidazoles 5 in good yield (Scheme 2).These products are decarboxylated 1:1 adducts of 1 and 4.A reaction mechanism is suggested in analogy to the previously reported reactions of 1 and NH-acidic heterocycles containing the CO-NH-CO-NH moiety (Scheme 5).The formation of ureas 6 and 7 can be rationalized by trapping the intermediate isocyanate F by an amine.No reaction is observed between 1 and 1,5,5- or 3,5,5-trisubstituted hydantoins in refluxing MeCN or i-PrOH, but an N-isopropylation of 1,5,5-trimethylhydantoin (8b) occurs in the presence of morpholine (Scheme 3).The reaction of the bis(azirine)dibromozink complex 11 and hydantoines 4 in refluxing MeCN yields zink complexes 12 of the corresponding 2-(1-aminoalkyl)-4H-imidazoles 5 (Scheme 4).